Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant Therapy (TNT) with Veliparib or Pembrolizumab in Rectal Cancer
NCT02921256Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of veliparib and pembrolizumab in rectal cancer (3 arms), sponsored by National Cancer Institute. Primary endpoint: Neoadjuvant Rectal Cancer Score up to 3 years. Started Jan 2017; status: completed.
02
Drugs
veliparibpembrolizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02921256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921256.